Journal Article

SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma

Ananthanarayanan, Preeta, Kopecka, Joanna, Sandri, Alberto, Scagliotti, Giorgio Vittorio, Papotti, Mauro Giulio, Leo, Francesco, Taulli, Riccardo, Ricci, Luisa, Bussolino, Federico, Gazzano, Elena, Riganti, Chiara, Bironzo, Paolo, Salaroglio, Iris Chiara, Novello, Silvia, Grosso, Federica, Belisario, Dimas Carolina, Napoli, Francesca, Facolmatà, Chiara, Comunanza, Valentina, Righi, Luisella, Fontana, Simona, Digiovanni, Sabrina, Libener, Roberta

2022

Overview

Background The combination of pemetrexed and cisplatin remains the reference first-line systemic therapy for malignant pleural mesothelioma (MPM). Its activity is moderate because of tumor aggressiveness, immune-suppressive environment and resistance to chemotherapy-induced immunogenic cell death (ICD). Preliminary and limited findings suggest that MPM cells have deregulated ubiquitination and proteasome activities, although proteasome inhibitors achieved disappointing clinical results. Methods Here, we investigated the role of the E3-ubiquitin ligase SKP/Cullin/F-box (SCF) complex in cell cycle progression, endoplasmic reticulum (ER)/proteostatic stress and ICD in MPM, and the therapeutic potential of the neddylation/SCF complex inhibitor MLN4924/Pevonedistat. Results In patient-derived MPM cultures and syngenic murine models, MLN4924 and cisplatin showed anti-tumor effects, regardless of MPM histotype and BAP1 mutational status, increasing DNA damage, inducing S- and G2/M-cell cycle arrest, and apoptosis. Mechanistically, by interfering with the neddylation of cullin-1 and ubiquitin-conjugating enzyme UBE2M, MLN4924 blocks the SCF complex activity and triggers an ER stress-dependent ICD, which activated anti-MPM CD8 + T-lymphocytes. The SKP2 component of SCF complex was identified as the main driver of sensitivity to MLN4924 and resistance to cisplatin. These findings were confirmed in a retrospective MPM patient series, where SKP2 high levels were associated with a worse response to platinum-based therapy and inferior survival. Conclusions We suggest that the combination of neddylation inhibitors and cisplatin could be worth of further investigation in the clinical setting for MPM unresponsive to cisplatin. We also propose SKP2 as a new stratification marker to determine the sensitivity to cisplatin and drugs interfering with ubiquitination/proteasome systems in MPM.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Animals / Antineoplastic Agents - pharmacology / Antineoplastic Agents - therapeutic use / Apoptosis / Biomedical and Life Sciences / Biomedicine / Cancer / Cancer Research / Carfilzomib / Cell death / Cell Line, Tumor / Chemotherapy / Cisplatin - pharmacology / Cisplatin - therapeutic use / DNA damage / endoplasmic reticulum stress / Enzyme Inhibitors - pharmacology / Enzyme Inhibitors - therapeutic use / Health aspects / Humans / Immune response / immunogenic cell death / Immunology / Ligases / Malignant pleural mesothelioma / Mesothelioma / Mesothelioma, Malignant - drug therapy / Mice / Oncology / Pemetrexed / Pemetrexed - pharmacology / Pemetrexed - therapeutic use / Pevonedistat / S-Phase Kinase-Associated Proteins - metabolism / SKP/Cullin/F-box complex / Ubiquitin